Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance
Authors:
Open Access
- 20 August 2024
- journal article
- research article
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (8) , 101686
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Intrinsic PD‐L1 promotes antitumor activity of CD8 + cytotoxic T lymphocytes via in cis interaction with CD80Cancer Communications, 2022
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studiesInternational Journal of Cancer, 2020
- Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosisCancer Reports, 2019
- Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade ImmunotherapyImmunity, 2019
- Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T CellsImmunity, 2019
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factorCancer Immunology, Immunotherapy, 2016
- A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host DiseaseTransplantation and Cellular Therapy, 2013
- T‐bet, a Th1 transcription factor regulates the expression of Tim‐3European Journal of Immunology, 2010
- Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune diseaseNature, 2002